Martin Hutchings, Andrew David Zelenetz, Jacob Haaber Christensen, Almudena Cascales Hernandez, Sarit E. Assouline, Luis E. Malpica Castillo, Shalin Kothari, Dipenkumar Modi, Miguel Ángel Canales Albendea, Damian Cubillas, Alejandro Martin Garcia-Sancho, Catherine S. Diefenbach, John Kuruvilla, Paolo Fabrizio Caimi, Krish Patel, Sean Landrette, Xin Zhi, Yuanyuan Zhang, Roland Meier, Matthew Matasar. "Phase 1 study of ARV-393, a PROTAC BCL6 degrader, as monotherapy in patients with advanced non-Hodgkin lymphoma (NHL) or combined with glofitamab in patients with diffuse large B-cell lymphoma (DLBCL).." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.tps7103